M21 D4: ECS - Gila Therapeutics from pyy Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 10 min 45 sec ✓ Published: 25-Oct-2021
Description: Gila Therapeutics|Scott Schorer, ME, President and CEO (scott.schorer@gilatherapeutics.com)nnImagine GLP-1 & PYY weight loss therapies with greater efficacy & no side effects, zero nausea. Gila is developing obesity therapies based on a newly discovered pathway connecting hormone receptors on the tongue directly to the brain's satiety centers.With topical lingual application of PYY, we showed a strong satiety response in mice - as much as a large meal or an injection of the hormone
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)